We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

Back to rankings

8 hedge funds and large institutions have $83.3K invested in Northwest Biotherapeutics, Inc. Common stock in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

91% more capital invested

Capital invested by funds: $43.7K → $83.3K (+$39.6K)

14% more funds holding

Funds holding: 7 → 8 (+1)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
8
Holders Change
+1
Holders Change %
+14.29%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KFA
Kelleher Financial Advisors
New York
+$41.3K
2
EFG
Ethos Financial Group
Pennsylvania
+$2.21K
3
ME
McIlrath & Eck
Washington
+$124

Top Sellers

Rank Fund Capital Flow
1
AMG
Advisors Management Group
Wisconsin
-$2K
2
WJWM
Williams Jones Wealth Management
New York
-$413
Name Holding Trade Value Shares
Change 		Change in
Stake
KFA
1
Kelleher Financial Advisors
New York
$41.3K +$41.3K +200,000 New
VWA
2
VSM Wealth Advisory
Maryland
$16.6K – – –
OCG
3
Opus Capital Group
Ohio
$12K – – –
EFG
4
Ethos Financial Group
Pennsylvania
$8.07K +$2.21K +10,720 +38%
WJWM
5
Williams Jones Wealth Management
New York
$5.16K -$413 -2,000 -7%
ME
6
McIlrath & Eck
Washington
$124 +$124 +600 New
AMG
7
Advisors Management Group
Wisconsin
– -$2K -10,270 Closed

NWBO Hedge Fund Activity: Q1 2026 in Review

8 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q1 2026, worth a combined $83.3K — up 91% from $43.7K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new NWBO positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Kelleher Financial Advisors, opening a new position worth an estimated $41.3K. The largest seller was Advisors Management Group, exiting entirely with an estimated $2K sold.

  • 8 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q1 2026, up from 7 in Q4 2025.
  • Funds reported $83.3K of Northwest Biotherapeutics, Inc. Common stock stock for Q1 2026, up 91% quarter-over-quarter.
  • 2 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q1 2026 and 1 closed out, a net change of +1 holder.
  • The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q1 2026 was Kelleher Financial Advisors, an estimated $41.3K added.
  • The largest Northwest Biotherapeutics, Inc. Common stock seller in Q1 2026 was Advisors Management Group, an estimated $2K sold.

Based on aggregated 13F filings for Q1 2026.